Peramivir API Manufacturers

compare suppliers & get competitive offers

Filters

Reset current filters

Type
Production region
Qualifications
Country of origin

HIGHLIGHTED

Located in:

China

Produced in:

China

Established in: 2013

MOQ: 1 kg

Employees: 25+

ISO9001 certified

Drug R&D center (in Hangzhou)

From lab scale (mg/g) to commercial scale (kgs/tons)

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • CoA

  • ISO9001

Distributor

Produced in:

World

Established in: 2005

MOQ: -

Employees: 200+

Portfolio of over 2,000 APIs

Precise quality control

End-to-end global regulatory support

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • DMF

  • CEP

  • GMP

  • CoA

  • MSDS

  • BSE/TSE

How does it work?

1
Register for free
icon

You can register for free as long as you are registering on behalf of a legal company related to the pharmaceutical industry

2
Start sourcing
icon

Search in the search bar the product that you’re looking for. We’ll show you an overview of all available suppliers. Use the filters to select the relevant suppliers only

3
Send inquiries
icon

Have you found interesting suppliers? Then it’s time to contact them. Use the send inquiry button and send them a message. You can send for each product, 3 inquiries per week

4
Get quotation
icon

Suppliers get notified by Pharmaoffer that they’ve received a new inquiry. They will come back to you with their questions, certificates, and offer in the chat on Pharmaoffer. We will send you an email in case of any news

5
Arrange agreement
icon

Does the supplier meet your quality and commercial requirements? Then you can place the order. Just follow the steps of our order module

Looking for Peramivir API 330600-85-6?

Description:
Here you will find a list of producers, manufacturers and distributors of Peramivir. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
API | Excipient name:
Peramivir 
Cas Number:
330600-85-6 
DrugBank number:
DB06614 
Unique Ingredient Identifier:
9ZS94HQO3B

About Peramivir

Why are professionals looking for Peramivir? Peramivir is an antiviral agent developed by Biocryst Pharmaceuticals to treat influenza A/B. The development of peramivir has been supported by the US Department of Health and Human Services as part of the government's effort to prepare for a flu pandemic. Being an influenza virus neuraminidase inhibitor, peramivir works by preventing new viruses from emerging from infected cells. Due to the poor oral bioavailability, the oral formulation of the drug was previously abandoned by Johnson and Johnson Company.

The injectable intravenous formulation of peramivir was approved by the FDA in September 2017 for the treatment of acute uncomplicated influenza to pediatric patients 2 years and older who have been symptomatic for no more than two days.

You can ask the supplier about all relevant certificates for the product such as CoA, Safety Data Sheet and DMF.

Peramivir is a type of Neuraminidase inhibitors


Neuraminidase inhibitors are a vital subcategory of pharmaceutical active pharmaceutical ingredients (APIs) used in the treatment and prevention of influenza viral infections. These medications target the neuraminidase enzyme, which plays a crucial role in the viral replication and spread within the body.

Neuraminidase inhibitors work by inhibiting the activity of the neuraminidase enzyme, thereby preventing the release of viral particles from infected cells. By blocking this process, these drugs effectively limit the spread of the influenza virus throughout the body, reducing the severity and duration of symptoms.

Oseltamivir and zanamivir are two well-known neuraminidase inhibitors commonly prescribed for the treatment and prophylaxis of influenza infections. Oseltamivir is available in oral capsule form, while zanamivir is administered via inhalation.

These pharmaceutical agents exhibit potent antiviral activity against both influenza A and B strains. They are particularly effective when initiated within the first 48 hours of symptom onset, as early treatment significantly reduces the risk of complications and hospitalization.

Neuraminidase inhibitors are considered a cornerstone in the management of influenza infections, especially during seasonal outbreaks and pandemics. They provide a valuable tool for healthcare professionals in controlling the spread of the virus and mitigating its impact on public health.

In conclusion, neuraminidase inhibitors represent a crucial subcategory of pharmaceutical APIs that effectively target the neuraminidase enzyme, playing a vital role in the treatment and prevention of influenza viral infections. These medications demonstrate strong antiviral activity and are instrumental in minimizing the severity and duration of influenza symptoms.


Peramivir (Neuraminidase inhibitors), classified under Anti-infective Agents


Anti-infective agents are a vital category of pharmaceutical active pharmaceutical ingredients (APIs) used in the treatment of various infectious diseases. These agents play a crucial role in combating bacterial, viral, fungal, and parasitic infections. The demand for effective anti-infective APIs has grown significantly due to the increasing prevalence of drug-resistant microorganisms.

Anti-infective APIs encompass a wide range of substances, including antibiotics, antivirals, antifungals, and antiparasitics. Antibiotics are particularly important in fighting bacterial infections and are further categorized into different classes based on their mode of action and target bacteria. Antivirals are designed to inhibit viral replication and are essential in the treatment of viral infections such as influenza and HIV. Antifungals combat fungal infections, while antiparasitics are used to eliminate parasites that cause diseases like malaria and helminthiasis.

The development and production of high-quality anti-infective APIs require stringent manufacturing processes and adherence to regulatory standards. Pharmaceutical companies invest heavily in research and development to discover new and more effective anti-infective agents. Additionally, ensuring the safety, efficacy, and stability of these APIs is of utmost importance.

The global market for anti-infective APIs is driven by factors such as the rising incidence of infectious diseases, the emergence of new and drug-resistant pathogens, and the growing demand for improved healthcare infrastructure. Continuous advancements in pharmaceutical technology and the development of innovative drug delivery systems further contribute to the expansion of this market.

In conclusion, anti-infective agents are a critical category of pharmaceutical APIs that play a pivotal role in treating infectious diseases. Their effectiveness in combating various types of infections makes them essential components in the arsenal of modern medicine.



Peramivir manufacturers | traders | suppliers

We have 2 companies offering Peramivir produced in 2 different countries.

Get in contact with the supplier of your choice:

  • Senova Technology Co., Ltd. from China, product country of origin China
  • LGM Pharma from United States, product country of origin World

Let the supplier know whether you are looking for a product with a specific monograph such as EP (Ph. Eur.), USP, JP, BP or another quality. Or, whether you are looking for hydrochloride (HCl), anhydricum, base, micronisatum or a specific purity.

You can use the filters to find high-quality suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our FAQ page or use the chat box in the corner to get more information about Pharmaoffer.